Abstract
A preclinical study on our previously discovered highly potent c-Met inhibitor 1 (zgwatinib) demonstrated its significant toxicity, and a SAR campaign was conducted to finely tune down the hERG inhibition without affecting the c-Met potency. Compounds 11, 12 and 39 stood out as new c-Met inhibitors with IC50 values of <3.0 nM and being nearly inactive against hERG channels.
Original language | English (US) |
---|---|
Pages (from-to) | 1423-1427 |
Number of pages | 5 |
Journal | MedChemComm |
Volume | 3 |
Issue number | 11 |
DOIs | |
State | Published - Nov 2012 |
Externally published | Yes |
ASJC Scopus subject areas
- Biochemistry
- Molecular Medicine
- Pharmacology
- Pharmaceutical Science
- Drug Discovery
- Organic Chemistry